此次获批标志着德琪医药在香港市场的进一步拓展，对公司业务发展意义重大，不仅彰显了公司在生物 制药领域研发和市场推广能力的持续增强，而且希维奥的获批将满足香港市场相关疾病治疗需求，提升 公司在生物科技行业的竞争力。 德琪医药-B(06996)涨近6%，截至发稿，涨5.34%，报4.34港元，成交额949.44万港元。 消息面上，香港卫生署已批准希维奥(塞利尼索)两项补充新药上市申请，分别用于治疗多发性骨髓瘤(与 硼替佐米和地塞米松联合使用，针对至少接受过一种治疗的成年患者)和复发性或难治性弥漫大B细胞淋 巴瘤(作为单药治疗方案，适用于经过至少两线系统性治疗且不符合造血干细胞移植的成人患者)。 ...

Core Viewpoint - Jichuan Pharmaceutical's subsidiary has received approval for a new drug, which is expected to positively impact the company's future development [1] Group 1: Drug Approval - Jichuan Pharmaceutical announced that its wholly-owned subsidiary, Jichuan Limited, has received a drug registration certificate from the National Medical Products Administration for the drug Marcilosavir Tablets [1] - The drug is classified as a Class 1 new drug and is a next-generation polymerase acidic protein (PA) nuclease inhibitor with broad-spectrum antiviral properties against influenza viruses [1] - The approved indication is for the treatment of previously healthy adults with uncomplicated influenza A and B [1] Group 2: Market Development and Uncertainties - The approval of this cooperative product is expected to have a positive effect on the company's future development [1] - However, the drug's market launch will require a development cycle and is subject to uncertainties influenced by pharmaceutical industry policies and procurement bidding [1]